Top-down ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
96クローン病6

96. クローン病


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-005702-37-NL
(EUCTR)
08/04/201512/02/2015Early infliximab use in kids with Crohn's disease (TISKids)Top-Down Infliximab Study in Kids with Crohn's disease (TISKids) - Top-down Infliximab in Kids with Crohn's disease (TISKids) Crohn's disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Inflectra
INN or Proposed INN: INFLIXIMAB
Other descriptive name: Inflectra
Erasmus Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 4Netherlands
2NCT02517684
(ClinicalTrials.gov)
April 20151/7/2015Top-down Infliximab Study in Kids With Crohn's DiseaseTop-down Infliximab Study in Kids With Crohn's DiseaseCrohn's DiseaseDrug: Infliximab;Drug: Prednisolone;Other: Exclusive enteral nutrition;Drug: AzathioprineErasmus Medical CenterZonMw: The Netherlands Organisation for Health Research and Development;Hospira, now a wholly owned subsidiary of PfizerActive, not recruiting3 Years17 YearsAll100Phase 4Belgium;Finland;Netherlands;Denmark;Italy;Poland
3EUCTR2012-000645-13-BE
(EUCTR)
09/09/201316/07/2013Infliximab as firsdt treatment instead of second line treatment in Crohns diseaseInfliximab Top-down Study in Kids with Crohn’s disease - ITSKIDS Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: RemicadeErasmusMCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Belgium;Netherlands
4NCT01880307
(ClinicalTrials.gov)
January 20137/6/2013Infliximab Top-down in Pediatric CrohnInfliximab Top-down Study in Kids With Crohn's DiseaseCrohn's DiseaseDrug: Azathioprine;Drug: Infliximab;Drug: PrednisolonErasmus Medical CenterUniversity of Roma La Sapienza;University Hospital, BrusselsTerminated3 Years17 YearsBoth13Phase 4Italy;Netherlands
5NCT01752790
(ClinicalTrials.gov)
December 201212/12/2012Efficacy and Safety of Top-down Therapy in Pediatric Crohn's DiseaseEfficacy and Safety of Infliximab as First-line Therapy in Pediatric Crohn's Disease: a Randomized, Controlled, Open-label TrialPediatric Crohn's DiseaseDrug: Top-down;Drug: Step-upUniversity of Roma La SapienzaNULLWithdrawn6 Years18 YearsBoth0Phase 4Italy
6EUCTR2012-000645-13-NL
(EUCTR)
17/10/201212/07/2012Infliximab as first treatment instead of second line treatment in Crohns diseaseInfliximab Top-down Study in Kids with Crohn’s disease - ITSKIDS Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: RemicadeErasmusMCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Belgium;Netherlands;Italy